Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>This study aimed to investigate the trends in serotypes and <em>in vitro</em> susceptibility of <em>Streptococcus pneumoniae</em> causing adult invasive pneumococcal disease (IPD) to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics from 2017 to 2020, following implementation of the 13-valent pneumococcal conjugate vaccine (PCV-13) and during the COVID-19 pandemic.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>During the study period, a total of 237 isolates of <em>S. pneumoniae</em> were collected from non-duplicate patients, covering 15% of IPD cases in Taiwan. Antimicrobial susceptibility testing was performed using the Sensititre® system (TREK Diagnostic Systems). A latex agglutination method (ImmuLex™ Pneumotest kit) was used to determine the serotypes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The susceptibility rates were high for vancomycin (100%), teicoplanin (100%), and linezolid (100%), followed by ceftaroline (non-meningitis) (98.3%), moxifloxacin (94.9%), and quinupristin/dalfopristin (89.9%). The MIC<sub>50</sub>s and MIC<sub>90</sub>s of dalbavancin, telavancin, tedizolid, eravacycline, and omadacycline were generally low for the isolates. Non-vaccine serotype 23A was the top cause of IPD across the adult age. Isolates of serotype 15B were slightly fewer than those of PCV-13 serotypes in patients aged >65 years. The overall case-fatality rate was 15.2% (36/237) but was especially high for non-PCV-13 serotype 15B (21.4%, 3/14). The vaccine coverage was 44.7% for PCV-13 and 49.4% for 23-valent pneumococcal polysaccharide vaccine (PPSV-23), but was 57% for both PCV-13 and PPSV-23.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>The incidence of IPD was stationary after PCV-13 introduction and only dramatically decreased in the COVID-19 pandemic in 2020. The MIC<sub>50</sub>s and MIC<sub>90</sub>s of dalbavancin, telavancin, tedizolid, eravacycline, omadacycline were generally low for <em>S. pneumoniae</em> causing adult IPD.</p>